These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 30051225)

  • 1. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance in China: current situation, successes and challenges.
    Zhang L; Wong LY; He Y; Wong IC
    Drug Saf; 2014 Oct; 37(10):765-70. PubMed ID: 25218237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.
    Zhang X; Niu R; Feng B; Guo J; Liu Y; Liu X
    Expert Opin Drug Saf; 2019 Jan; 18(1):59-68. PubMed ID: 29883236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active pharmacovigilance in China: recent development and future perspectives.
    Li X; Li H; Deng J; Zhu F; Liu Y; Chen W; Yue Z; Ren X; Xia J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):863-871. PubMed ID: 29637279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in China: Evolution and future challenges.
    Song H; Pei X; Liu Z; Shen C; Sun J; Liu Y; Zhou L; Sun F; Xiao X
    Br J Clin Pharmacol; 2023 Feb; 89(2):510-522. PubMed ID: 35165914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.
    Al Hail M; Elkassem W; Hamad A; Abdulrouf P; Thomas B; Stewart D
    Int J Clin Pharm; 2018 Aug; 40(4):769-774. PubMed ID: 29616393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Scenario and Future Prospects of Adverse Drug Reactions (ADRs) Monitoring and Reporting Mechanisms in the Rural Areas of India.
    Shukla S; Sharma P; Gupta P; Pandey S; Agrawal R; Rathour D; Kumar Kewat D; Singh R; Kumar Thakur S; Paliwal R; Sulakhiya K
    Curr Drug Saf; 2024; 19(2):172-190. PubMed ID: 37132145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil.
    Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y
    Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of pharmacovigilance and reporting of adverse drug reactions in hospitals: a cross-sectional study in China.
    Zhao Z; Shen J; Shen C; Zhu B; Sun J; Yu J; Sun F; Song H
    Curr Med Res Opin; 2021 Nov; 37(11):2001-2006. PubMed ID: 34376068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.
    Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O
    Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.